Advertisement

Topics

Pfizer’s Besponsa Receives FDA Approval for Treatment of Acute Lymphoblastic Leukemia

16:21 EDT 17 Aug 2017 | Speciality Pharma Journal

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1 BESPONSA was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs. “The approval of BESPONSA is an …

Original Article: Pfizer’s Besponsa Receives FDA Approval for Treatment of Acute Lymphoblastic Leukemia

NEXT ARTICLE

More From BioPortfolio on "Pfizer’s Besponsa Receives FDA Approval for Treatment of Acute Lymphoblastic Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...